Type 2 diabetes medication comparison

Mounjaro vs Januvia: injection, tablet, switching, and combination questions

Compare Mounjaro tirzepatide injection with Januvia sitagliptin tablets using current labels and 2026 diabetes guidance, including route, kidney, side-effect, switching, and concurrent-use questions.

Educational guideUpdated August 9, 2026

How to compare Mounjaro and Januvia safely

Confirm the exact products and goal: Mounjaro tirzepatide injection, Januvia sitagliptin tablets, type 2 diabetes control, side-effect review, coverage, or a clinician-directed change.

Compare the routines: once-weekly subcutaneous Mounjaro versus once-daily oral Januvia, without inventing a tablet-to-injection dose conversion.

Review A1C and glucose patterns, kidney function, gastrointestinal symptoms, pancreatitis history, gallbladder concerns, heart-failure history, skin symptoms, and severe joint pain.

Reconcile insulin, sulfonylureas, other incretin medicines, oral contraceptives, narrow-therapeutic-index oral medicines, and every prescription or supplement.

Ask the prescriber for a documented continue, stop, start, monitoring, sick-day, procedure, refill, and follow-up plan rather than overlapping or switching from online advice.

Direct answer

Mounjaro and Januvia are different prescription medicines for type 2 diabetes, not dose-equivalent substitutes. Mounjaro contains tirzepatide, a once-weekly injectable dual GIP/GLP-1 receptor agonist; its current label includes adults and pediatric patients age 10 and older. Januvia contains sitagliptin, an oral DPP-4 inhibitor taken once daily for adults, with kidney-function-based dose selection. The American Diabetes Association’s 2026 Standards of Care says concurrent use of a DPP-4 inhibitor with a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist is not recommended because it does not add glucose lowering beyond GLP-1–based therapy. Do not stop Januvia, start Mounjaro, overlap them, or use a copied conversion schedule on your own. A prescriber should review the treatment goal, A1C and glucose pattern, kidney function, other diabetes medicines, stomach symptoms, pancreatitis history, cost, coverage, and follow-up before changing the plan.

Identity and label fit

Mounjaro is a weekly dual-incretin injection; Januvia is a daily DPP-4 tablet

Mounjaro contains tirzepatide and activates GIP and GLP-1 receptors. Its April 22, 2026 manufacturer label covers glycemic control with diet and exercise in adults and pediatric patients age 10 and older with type 2 diabetes and includes several injection presentations. Januvia contains sitagliptin, inhibits DPP-4, and is taken orally once daily for adults with type 2 diabetes. The current Januvia label says pediatric safety and effectiveness have not been established. Route, age language, mechanism, presentation, and monitoring should be verified from the exact current label rather than reduced to “shot versus pill.”

Mounjaro is the tirzepatide brand for type 2 diabetes; Zepbound has distinct chronic weight-management and obstructive-sleep-apnea label contexts.
Januvia is not an FDA-approved weight-loss medicine, and Mounjaro should not be presented as a no-prescription or guaranteed weight-loss product.
Peptide12 serves adults; that care boundary does not change or erase the current manufacturer Mounjaro label’s pediatric type 2 diabetes indication.

Together or switching

Current diabetes guidance does not recommend routine concurrent use

Recommendation 9.18 in the American Diabetes Association’s 2026 Standards of Care states that concurrent use of a DPP-4 inhibitor with a GLP-1 receptor agonist or a dual GIP/GLP-1 receptor agonist is not recommended because it does not add glucose lowering beyond GLP-1–based therapy. That directly applies to the class question raised by Januvia and Mounjaro. It does not create a universal at-home stop date, washout interval, starting schedule, or dose conversion. The prescriber still needs to decide why the plan is changing, which product continues, how other glucose-lowering medicines are handled, and when response and tolerability will be reassessed.

Do not overlap Mounjaro and Januvia merely to “boost” an incretin effect or use leftover tablets during an injection refill delay.
Do not stop Januvia or begin Mounjaro from a search snippet; the clinician should document the last and first treatment timing and glucose-monitoring plan.
Insulin and sulfonylureas can increase hypoglycemia risk when the glucose-lowering plan changes, so their review belongs to the prescriber rather than an online conversion chart.

Safety and monitoring differences

Kidney dosing, gastrointestinal effects, pancreas warnings, and other risks are not interchangeable

Current Mounjaro labeling includes a boxed warning about thyroid C-cell tumor findings in rats and contraindications involving personal or family medullary thyroid carcinoma or MEN 2. It also addresses pancreatitis, hypoglycemia with insulin or secretagogues, severe gastrointestinal reactions, kidney injury related to volume depletion, diabetic-retinopathy complications, gallbladder disease, hypersensitivity, and aspiration around anesthesia or deep sedation. Januvia labeling also addresses pancreatitis and hypoglycemia with insulin or secretagogues, while adding product-specific kidney-dose selection, heart-failure risk assessment, severe joint pain, and bullous pemphigoid warnings. A shared diabetes indication does not make these safety profiles equivalent.

Januvia dosing depends on estimated kidney function; Mounjaro gastrointestinal fluid loss can also make kidney and hydration review important even though the dosing questions differ.
Severe persistent abdominal pain, repeated vomiting, inability to keep fluids down, markedly reduced urination, fainting, trouble breathing, facial or throat swelling, or rapidly worsening symptoms needs prompt assessment.
New blisters or erosions, severe persistent joint pain, heart-failure symptoms, significant glucose changes, or concerning eye symptoms should be reported through the responsible clinical pathway.

Routine, access, and product quality

Convenience and cost depend on the whole care pathway—not route alone

A once-daily tablet may fit one person’s routine better, while another may prefer a weekly injection, but route alone does not determine clinical fit. Compare insurance criteria, prior authorization, pharmacy stock, copays or cash cost, injection supplies, storage, travel, kidney or glucose follow-up, side-effect support, and refill continuity. Mounjaro delays gastric emptying and has presentation-specific instructions plus oral-hormonal-contraceptive counseling after initiation and dose escalation. Januvia requires the correct tablet strength for kidney function. These practical details should be settled before a change rather than after a missed refill.

Confirm the exact Mounjaro presentation and the exact Januvia tablet strength, manufacturer label, dispensing pharmacy, coverage terms, and follow-up contact.
Avoid research-use tirzepatide, “generic Mounjaro,” no-prescription Januvia, copied injection or conversion schedules, hidden pharmacy sourcing, and guaranteed A1C or weight outcomes.
A patient-specific compounded tirzepatide prescription is not FDA-approved Mounjaro or an FDA-approved generic finished drug product and may differ in concentration, inactive ingredients, container, labeling, storage, and supplies.

Patient safety checklist

Questions to ask before changing Mounjaro or Januvia

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact product, presentation or tablet strength, indication, prescription label, prescriber, and dispensing pharmacy apply?

✓

What problem is the change intended to solve: A1C, glucose variability, side effects, kidney dosing, adherence, coverage, refill access, or another documented goal?

✓

What are my recent A1C, fasting and after-meal readings or CGM pattern, eGFR, creatinine, urine findings, weight trend, blood pressure, and eye-history findings?

✓

Have pancreatitis, gallbladder disease, severe gastrointestinal symptoms, gastroparesis, dehydration, kidney disease, heart failure, severe joint pain, blistering skin disease, MTC or MEN 2 history, and pregnancy plans been reviewed?

✓

Do insulin, a sulfonylurea, another GLP-1 or DPP-4 medicine, oral contraceptives, narrow-therapeutic-index oral medicines, diuretics, or supplements change the plan?

✓

If Januvia is being stopped, when is the last tablet; if Mounjaro is being started, which exact presentation and clinician-directed timing apply?

✓

What glucose, kidney, hydration, gastrointestinal, eye, skin, joint, and follow-up monitoring is needed after the change?

✓

Who handles prior authorization, pharmacy delays, side effects, missed treatment, urgent symptoms, and the next treatment decision?

FAQs

Short answers for patients

Is Mounjaro the same as Januvia?

No. Mounjaro is tirzepatide, a once-weekly injectable dual GIP/GLP-1 receptor agonist. Januvia is sitagliptin, a once-daily oral DPP-4 inhibitor. They have different mechanisms, routes, label details, warning profiles, kidney considerations, and monitoring needs.

Can Mounjaro and Januvia be taken together?

The American Diabetes Association’s 2026 Standards of Care does not recommend concurrent DPP-4 inhibitor use with a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist because it does not add glucose lowering beyond GLP-1–based therapy. Do not overlap or stop either medicine on your own; ask the prescriber for a specific transition and monitoring plan.

Which is better for type 2 diabetes: Mounjaro or Januvia?

There is no universal better medicine. The choice depends on individualized glycemic goals, kidney function, gastrointestinal tolerance, pancreatitis and gallbladder history, heart-failure context, other diabetes medicines, route preference, coverage, cost, and follow-up. A label or guideline comparison cannot select treatment for one person.

Can I switch from Januvia to Mounjaro without a gap?

Do not apply a universal gap or dose-conversion rule. The prescriber should confirm why the plan is changing, the last Januvia tablet, the exact Mounjaro presentation and start timing, other glucose medicines, glucose-monitoring needs, side-effect instructions, and follow-up.

Does Januvia need a kidney dose adjustment?

The current Januvia label requires kidney-function assessment before starting and periodically afterward, with lower daily strengths for specified reduced-eGFR ranges. Do not select or split a tablet strength from an online summary; use the prescription and current manufacturer label.

Is Mounjaro a weight-loss drug while Januvia is only for diabetes?

Mounjaro is FDA-approved for type 2 diabetes, not as the tirzepatide chronic weight-management brand. Zepbound carries tirzepatide weight-management and obstructive-sleep-apnea label contexts. Januvia is also diabetes-labeled and is not an FDA-approved weight-loss medicine.

Is compounded tirzepatide generic Mounjaro?

No. A patient-specific compounded tirzepatide preparation is not FDA-approved Mounjaro or an FDA-approved generic finished drug product. It may differ in concentration, inactive ingredients, container, labeling, storage, supplies, and pharmacy instructions.

What are red flags for online Mounjaro or Januvia sellers?

Red flags include no-prescription checkout, research-use tirzepatide marketed to patients, “generic Mounjaro,” automatic approval, copied overlap or conversion schedules, guaranteed A1C or weight-loss claims, hidden pharmacy identity, unclear tablet or injection labeling, and no adverse-event or follow-up pathway.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current MOUNJARO prescribing information — effective April 22, 2026 DailyMed: Manufacturer JANUVIA prescribing information American Diabetes Association: Pharmacologic Approaches to Glycemic Treatment — Standards of Care in Diabetes 2026 MedlinePlus: Tirzepatide injection drug information — revised February 15, 2026 MedlinePlus: Sitagliptin drug information FDA: Compounding and the FDA — Questions and Answers FDA BeSafeRx: Safe online pharmacy information Peptide12: Mounjaro prescription online Peptide12: Mounjaro vs Jardiance Peptide12: Mounjaro vs Farxiga Peptide12: Mounjaro prior authorization Peptide12: GLP-1 glucose monitoring Peptide12: GLP-1 low blood sugar Peptide12: Kidney disease care questions Peptide12: Fake GLP-1 pharmacy checklist Peptide12: How online peptide therapy works